Search
EGF receptor (EGFR) inhibitor
Adverse effects:
- rash (acneiform eruption)
- topical clindamycin 2% plus hydrocortisone 1% lotion BID until resolution of the rash, plus minocycline 100 mg PO BID for a minimum of 4 weeks & continuing until resolution of the rash (NGC [CancerControl Alberta]) [1]
- paronychia [1]
- interstitial lung disease [2] Mechanism:
- inhibits EGF receptor
Interactions
drug adverse effects (more general classes)
Specific
afatinib (Gilotrif)
cetuximab (Erbitux)
erlotinib (Tarceva)
gefitinib (Iressa)
necitumumab (Portrazza)
osimertinib (Tagrisso)
panitumumab (Vectibix)
General
antineoplastic tyrosine kinase inhibitor
Properties
INHIBITS: protein kinase
References
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
- Rosell R, Carcereny E, Gervais R et al
Erlotinib versus standard chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):
a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 2012 Mar;13(3):239-46.
PMID: 22285168 Clinical Trial.